We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01399840
First Posted: July 22, 2011
Last Update Posted: September 15, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Medivation, Inc.
Information provided by (Responsible Party):
Pfizer
July 13, 2011
July 22, 2011
September 15, 2017
June 30, 2011
March 31, 2014   (Final data collection date for primary outcome measure)
The primary outcome of this study is to determine the MTD of daily oral BMN 673 in patients with AML and MDS (Arm 1) and patients with CLL and MCL (Arm 2). [ Time Frame: Assessed after each visit until completion (Estimated duration is 12-18 months) ]
Same as current
Complete list of historical versions of study NCT01399840 on ClinicalTrials.gov Archive Site
  • Number of participants with adverse events [ Time Frame: Assessed after each visit until completion of the study (Estimated duration is 24-30 months) ]
  • Determine the pharmacokinetic (PK) profile of BMN 673 [ Time Frame: Assessed at each visit in cycle 1 - 5 (Estimated duration is 24 months) ]
    Sample collection times vary per visit. PK parameters that will be evaluated include: maximum concentration (Cmax), minimum concentration (Cmin), time to maximum plasma concentration (Tmax), area under the curve from 0 to last quantifiable sampling point postdose (AUC0-inf), area under the curve extrapolated to infinity (AUC0-last), half life (t1/2), systemic clearance (CL/f) and volume of ditribution (VZ/f)
  • Determine the Recommended Phase 2 Dose (RP2D) of oral daily BMN 673 [ Time Frame: Assessed after each visit until completion of the study (Estimated duration is 24-30 months) ]
  • Assess preliminary efficacy of BMN 673 by evaluating per response publications [ Time Frame: Assessed approximately every 4-12 weeks (Estimated duration is 24-30 months) ]
Same as current
Not Provided
Not Provided
 
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Phase 1, Two-arm, Open-label Study Of Once Daily, Oral Bmn 673 In Patients With Advanced Hematological Malignancies
This is a two-arm, open-label study to determine the maximum tolerated dose (MTD) and assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of BMN 673 in patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL). Arm 1 will enroll patients with either AML or MDS; Arm 2 will enroll patients with either CLL or MCL.
Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome
  • Chronic Lymphocytic Leukemia
  • Mantle Cell Lymphoma
Drug: BMN 673
Oral capsule with multiple dosage forms given once daily
  • Experimental: Arm 1: BMN 673
    Arm 1 will enroll patients with either AML or MDS
    Intervention: Drug: BMN 673
  • Experimental: Arm 2: BMN 673
    Arm 2 will enroll patients with either CLL or MCL
    Intervention: Drug: BMN 673
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
33
May 31, 2014
March 31, 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. 18 years of age or older.
  2. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
  3. Arm 1 AML/MDS: Must have available tissue
  4. Arm 2 CLL/MCL: Must have available tissue
  5. Have adequate organ function as defined below:

    1. Serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 2.5 X upper limit of normal (ULN);
    2. Total serum bilirubin ≤ 1.5 X ULN;
  6. Able to take oral medications
  7. Recovered from acute toxicity of prior treatment
  8. Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures.
  9. If sexually active, must be willing to use an acceptable method of contraception during therapy and for 30 days after the last dose of BMN 673.
  10. If female of childbearing potential, must have a negative serum pregnancy test at screening and be willing to have additional pregnancy tests during the study.
  11. Willing and able to comply with all study procedures.

Exclusion Criteria:

  1. Acute promyelocytic leukemia, APL [AML with t(15;17)(q22;q12), PML-RARA and variants].
  2. Disease-specific exclusion criteria:

    a. AML: i. Marrow cellularity < 25% ii. Circulating blasts > 50,000/mm3 b. MCL and CLL: i. Platelet count < 50,000/mm3 ii. Neutrophil count < 1000/mm3

  3. Autologous bone marrow transplant < 6 months before Cycle 1 Day 1
  4. Prior allogeneic bone marrow transplant < 6 months before Cycle 1 Day 1 and/or with the presence of graft versus host disease (GVHD)
  5. Prior treatment:

    1. AML: anti-leukemia treatment within 14 days before Cycle 1 Day 1; hydroxyurea treatment within 7 days before Cycle 1 Day 1.
    2. CLL, MCL or MDS: anti-lymphoma/leukemia treatment within 28 days before Cycle 1 Day 1;
  6. CLL/MCL patients who have received transfusion, hematopoietic growth factors within 7 days before Cycle 1 Day 1.
  7. Symptomatic central nervous system (CNS) involvement.
  8. Known to have human immunodeficiency virus (HIV) or active hepatitis C virus (HCV) or hepatitis B virus (HBV).
  9. Major surgery within 28 days before Cycle 1, Day 1.
  10. Active peptic ulcer disease.
  11. Active gastrointestinal tract disease with malabsorption syndrome.
  12. Requirement for IV alimentation.
  13. Prior surgical procedures affecting absorption.
  14. Uncontrolled inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).
  15. Myocardial infarction within 6 months before Cycle 1 Day 1, symptomatic congestive heart failure (New York Heart Association > class II), unstable angina, or unstable cardiac arrhythmia requiring medication.
  16. Breastfeeding at screening or planning to become pregnant (self or partner) at any time during study participation.
  17. Use of any investigational product or investigational medical device within 28 days before Cycle 1, Day 1.
  18. Concurrent disease or condition that would interfere with study participation or safety, such as:

    1. CLL/MCL patients with active, clinically significant infection requiring the use of parenteral anti-microbial agents, or grade > 2 infection by NCI CTCAE (v4.03) within 14 days before Cycle 1, Day 1(AML/MDS patients with controlled infection are eligible for the study with no specific time requirement prior to Cycle 1, Day 1);
    2. Clinically significant bleeding diathesis or coagulopathy, including known platelet function disorders;
    3. Non-healing wound, ulcer, or bone fracture.
  19. Patients who have received prior treatment with a PARP inhibitor are not eligible for Part 2 of the study (expansion), but are eligible for Part 1 (dose escalation) of the study.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom,   United States
 
 
NCT01399840
PRP-002
2010-023964-42 ( EudraCT Number )
C3441022 ( Other Identifier: Alias Study Number )
Not Provided
Not Provided
Plan to Share IPD: No
Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests
Pfizer
Pfizer
Medivation, Inc.
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
September 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP